# Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

> **NCT02870205** · PHASE3 · COMPLETED · sponsor: **Glenmark Specialty S.A.** · enrollment: 1176 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis (SAR)

## Interventions

- **DRUG:** GSP 301 NS
- **DRUG:** GOM-NS
- **DRUG:** GMM-2 NS
- **DRUG:** GSP 301 placebo NS

## Key facts

- **NCT ID:** NCT02870205
- **Lead sponsor:** Glenmark Specialty S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 1176 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02870205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02870205, "Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02870205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*